Compare NFG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFG | RYTM |
|---|---|---|
| Founded | 1902 | 2008 |
| Country | United States | United States |
| Employees | N/A | 414 |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.2B |
| IPO Year | 1997 | 2017 |
| Metric | NFG | RYTM |
|---|---|---|
| Price | $81.91 | $91.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $102.00 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 803.8K | 699.4K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 576.19 | 28.34 |
| EPS | ★ 4.58 | N/A |
| Revenue | ★ $2,277,541,000.00 | N/A |
| Revenue This Year | $15.04 | $55.34 |
| Revenue Next Year | $23.44 | $86.06 |
| P/E Ratio | $17.88 | ★ N/A |
| Revenue Growth | ★ 17.11 | N/A |
| 52 Week Low | $77.22 | $58.71 |
| 52 Week High | $97.06 | $122.20 |
| Indicator | NFG | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 53.32 |
| Support Level | $80.78 | $79.72 |
| Resistance Level | $83.08 | $92.17 |
| Average True Range (ATR) | 1.81 | 4.97 |
| MACD | 0.41 | -0.06 |
| Stochastic Oscillator | 43.31 | 55.56 |
National Fuel Gas Co is a diversified energy company involved in natural gas production, gathering, transportation, distribution, and marketing. It operates through three segments: Integrated Upstream and Gathering, Pipeline and Storage, and Utility. The majority of revenue comes from the Integrated Upstream and Gathering segment, which focuses on Seneca's natural gas exploration and development in the Appalachian region and Midstream operations supporting gas processing and gathering. The Pipeline and Storage segment transports and stores natural gas for customers in the northeastern United States and Canada, while the Utility segment supplies natural gas to retail customers in western New York and northwestern Pennsylvania. the company opeartes in United States.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.